Skip to main content

Table 1 Demographic characteristics and primary outcome measure, the number of active lesions/scan (Mean [SEM])

From: Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

Patient

Age

Sex

EDSS

Duration of disease

Mean number of active lesions per monthly scan

Change, mean lesion number

  

F/M

 

years

baseline period

treatment period

%

All patients

32.7 [1.4]

8/1

1.5 [0.33]

6.3 [2.0]

3.55 [0.78]

2.15 [0.69]

- 39.4

p = 0.013*

01

25

F

0

1

1

0,5

- 50

02

32

F

0

2.5

1.83

0

- 100

03

31

F

2.0

5

7.67

5.83

- 34

04

34

F

1.5

4

2.33

2.83

+ 21

05

34

F

1.0

0.3

6

3.67

- 38

06

36

M

2.5

11.3

4.5

0.67

- 85

07

40

F

2.5

15

1

0.17

- 83

08

33

F

2.5

15

4.83

4.17

- 14

09

30

F

1.5

3

2.67

1.5

- 38

     

Median change

- 43.8 %

     

Mean change

- 46.4 %

  1. * p for testing baseline vs. treatment period (Wilcoxon Matched-Pairs Signed-Ranks test for related samples).